Anuh Pharma Limited has informed the Exchange regarding the Audited Financial Results for the Board meeting held on May 23, 2025.

Revenue growth above 20%EBITDA margin compressionResults View source PDF Explain this filing

ANUHPHR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.6%Reaction day

₹100.50

prior close

₹102.50

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.6%+2.0% vs market

Pharmaceuticals peers, median of 148sector+0.4%+2.2% vs sector

On the reaction day the stock moved 2.0 pts more than Nifty Microcap 250 and 2.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

+1.5

15m

+1.4

30m

+0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.6+0.6+2.0+0.4+2.2

Next day

+5.0+0.5+4.5+0.3+4.6

+6.0+0.8+5.2+0.5+5.5

+6.0+1.2+4.8+1.0+5.0

+4.8+1.5+3.3+0.6+4.2

+8.6+1.6+7.0-0.1+8.7

+7.5+1.8+5.7+0.1+7.4

15d

+5.8+3.3+2.5+1.5+4.3

+3.3+3.1+0.2-1.2+4.5

-3.5+2.3-5.8+0.9-4.4

-12.9+0.2-13.1-1.6-11.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 148Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Anuh Pharma Limited has submitted its audited financial results to the NSE following a board meeting held on May 23, 2025. The filing is a standard compliance disclosure informing the exchange that the board has approved and released the company's audited financial performance. Detailed figures such as revenue, profit after tax, margins, and auditor observations are not included in the headline and would need to be reviewed in the full results document. This is a routine regulatory filing tied to the company's annual results announcement.

Likely market impact

No immediate stock price impact is expected from the filing itself, as it is a procedural disclosure confirming submission of results. Investors should review the detailed audited numbers separately to assess the company's actual financial performance and any year-on-year trends.

By the numbersStandalone · Q4 FY25 vs Q4 FY24

	Q4 FY25	Q4 FY24	Change
Revenue	₹198.1 Cr	₹163.9 Cr	+20.9%
Operating profit	₹15.88 Cr	₹16.90 Cr	−6.0%
Profit after tax	₹12.46 Cr	₹15.36 Cr	−18.9%
EBITDA margin	9.4%	11.7%	−2.3 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.